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A European patent law for blotechnologyC1) 
---------------------------------· -------
Today, the Comm I ss I on adopted Lord Cock f I e Id's p·roposa I for a 
draft d I reot I ve to app,·rox I mate nat Iona I I aws govern Ing 
Intellectual property rights for blotechnologlcal Inventions. The 
proposal has two main features: to enhance the legal certainty of 
obtaining patent protection for Inventions where various forms of 
animate matter are concerned; and to establlsh the conditions for 
the proper f unct I on Ing of the I nterna I market In b I otechno I ogil ea I 
goods. 
Jbe present posttlon and why It needs ta be Improved ,, 
The present situation In the Community Is that the relevant 
International conventions (Paris 1961; Strasbourg 1963) to which 
Member States are party were drawn up at a time when 
b I otechno I og I ea I processes were e I ther non-ex I stent or In the·I r 
Infancy. Adaptation of the texts of these conventfons tb cover 
these new processes and products n~ver took place W·lth the result 
that natlonal Interpretation of the cbnventlons diverged 
considerably. For example, a European patent In the 
blotechnologlcal fleld, registered at the Patent Office In 
Munich, may well have Its valldlty disputed In one Member State 
or another, because blotechnologlcal processes or products would 
not be considered patentable In that Member State. Lack of legal 
certainty, and lack of sufficient protection, Is commonplace tn 
the Community In this fleld. 
Improvement Is necessary both In order to Introduce greater t•gal 
certainty and because of the disadvantages under which Community 
Innovators In th Is f I e Id I abour compared w Ith the I r compet I to.rs 
In the US and Japan whose leglslatlon provides considerably mQre 
protection through patentabl I lty than Is currently aval table ,Jn 
Europe. ·The United States Patent and Trademark Office has already 
granted a patent on a man-made mouse from Harvard University as 
wel I as patents on plants. In Japan, several patent appllcatlons 
for plants and anlmals are expected to be granted shortly. The 
European Patent Office In Munich has recently given notice of Its 
Intention to grant a patent for a genetically engineered plant 
but hundreds of appllcatlons for plants and animals have yet to 
be examined. 
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The 11nk with the internal market 
As far as the Internal market Is concerned, the adoption of a 
Community directive with the consequent minimising of the 
differences In legal protection for these kinds of Inventions 
,throughout the Community can be expected to Induce greater Intra-
Community trade. Companies wlll be able to treat the common 
market as a single environment for their economic activities. 
This, combined with the extra Incentive offered by patentablllty 
to engage In blotechnologlcal research, wlfl In turn allow 
European Industry to compete more effectively In world markets. 
content of the directive: 
The directive provides answers to many of the legal Questions 
raised by Inventions In biotechnology such as: 
A patent can be granted on a living organism? Answer: Yes. 
How far does the patent law concept of discoveries exclude pre-
existing I lvlng matter from patentablllty? Answer: It does not 
exclude It provided that a sufficient degree of human 
Intervention has occurred. 
How far do patent rights extend In patented but self-repl·lcatlng 
Inventions? Answer: In all subsequent generations for the llfe of 
the patent (20 years from date of flllng). 
What Is the result In patent law of the exclusion of° plant and 
animal varieties from patentabl llty? Answer: Plants and anlmals 
are patentable If the patentablllty conditions of novelty, 
Invention and lndustrlal appllcablllty are met. 
Can a deposit of a mlcroorganlsm fulfll the patent law 
reQulrement of a repeatable dlsclosure of the Invention? Answer: 
l ' 
Yes. Likewise a patent granted on the basis of a deposited sample 
of the patented material would not be declared lnvalld In 
subseQuent patent lltlgatlon for lack of sufficient disclosure of 
the Invention. 
Alongside the procedural Improvements envisaged by the directive, 
an Improved system of patenting blotechnologlcal Inventions Is 
foreseen. One of the primary goals of the directive Is to ensure 
broad protection of both the various techniques of alterlng 
llvlng organisms as wel I as the modified organisms themselves. 
the practical effects expected from the proposed directive wlll 
be to recognise the patentablllty of genetlcal ly engineered 
products such as enhanced mlcroorganlsms, plants and animals. 
I 
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Practical applications have already arisen for genetically 
modified mlcroorganlsms In the fields of pollutlon control, toxic· 
waste treatment and mlcroblal enhanced oll recovery. Once the 
directive Is Implemented, such mlcroorganlsms and their 
Industrial appl lcatlons wl II enjoy a clearer and more certain 
legal protection In al I of the Member States of the Community and 
not Just those few with developed patent practice and 
Jurisprudence. 
Improved plants, such as those with resistance to diseases, 
pests, drought, salt, pesticides and herbicides, wlll be 
patentable. New genetic matertal Inserted Into plants and antmals 
wl It be considered patentable. The scope of patent rights In 
self-reproducing materlal WIii be defined so that the 
unauthorised use of such material for commercial multlpllcatlon 
and reproduction wlll fall within the patent rights. An example 
of this principle would be In the sale of patented barley for the 
production of beer: no royattles would be payable for such beer 
production. But If a purchaser of patented barley which was sold 
for the purpose of brewing beer, plants the barley and harvests a 
crop without authorisation, the patent rights would not be 
exhausted. 
New patent protection end plant variety protection: 
A specific problem needs to be addressed to take account of the 
already existing system of plant variety protection. The 
Commission therefore decided not to propose product patent 
protection for plants where they have been produced by the use of 
a known blotechnologlcal process. ·For patented plant mat~rtal 
which Is thereafter Incorporated Into plant varieties, a system 
of licensing between the patent rights and the breeders' rights 
Is envisaged to ensure a beneficial dispersal of the break 
throughs achieved with blotechnology. 
New aatent protection for animals: 
Improvements In anlmal farming expected to benefit from the 
proposed directive Include the genetic enhancement of breeding 
stock, greater control, flexlblllty and precision In breeding 
methods, prevention and control of disease, as well as the 
development of animals for medical and pharmaceuttcal research. 
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